VJOncology is committed to improving our service to you

ESMO 2020 | Ripretinib IPDE following disease progression in GIST

VJOncology is committed to improving our service to you

Filip Janku

Filip Janku, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses results from a Phase I study (NCT02571036) in which ripretinib intra-patient dose escalation (IPDE) following disease progression provided clinically meaningful progression-free survival (PFS) in gastrointestinal stromal tumor (GIST). The Phase III INTRIGUE study (NCT03673501) will evaluate ripretinib vs sunitinib in 2nd-line GIST. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter